Healthcare reality of the treatment of the high-risk multiple myeloma in Spain | Medicina Clínica (English Edition)
Emerging immunotherapies in multiple myeloma | The BMJ
Multiple myeloma | Nature Reviews Disease Primers
Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® (carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
Efficacy and Safety of Carfilzomib, Lenalidomide and Dexamethasone in MM | Research To Practice
Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France — a cohort study using the French National Healthcare database (SNDS) | Annals of Hematology
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
Baseline Characteristics of Patients With Multiple Myeloma According to... | Download Table
Cancers | Free Full-Text | Genome Instability in Multiple Myeloma: Facts and Factors
Current Oncology | Free Full-Text | Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
Clinical Trials in R/R Multiple Myeloma
Biomedicines | Free Full-Text | Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting
ASPIRE Trial - KRd VS Rd - Multiple Myeloma Clinical Trials
Amgen's Phase III ASPIRE trial of myeloma treatment Kyprolis meets primary endpoint - Clinical Trials Arena
Patient characteristics of 130 relapse and refractory multiple myeloma... | Download Scientific Diagram
Multiple #Myeloma is a... - Dr. Reddy's Laboratories Ltd. | Facebook
Efficacy and safety of carfilzomib for the treatment of multiple myeloma: An overview of systematic reviews - ScienceDirect
Kyprolis® Treatment for Patients With Multiple Myeloma - CancerConnect
Additional Abstracts of Interest in Multiple Myeloma at ASH 2015 | Research To Practice
Frontiers | Therapeutic strategies to enhance immune response induced by multiple myeloma cells
Cardiovascular Complications of Novel Multiple Myeloma Treatments | Circulation
